Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their claim with a new-and-improved BCMA CAR-T therapy?

Poseida Therapeutics is aiming to find that out in the very near future.

Eric Ostertag

The San Diego-based biotech filed their S-1 on a busy Friday, just ahead of the big JPMorgan confab that gets underway Monday morning in San Francisco. In it, they lay out an early snapshot on Phase I data for P-BCMA-101 targeting multiple myeloma ? a familiar target in the CAR-T world these days.